Efficacy and safety of nedaplatin versus cisplatin plus fluorouracil for treatment of esophageal neoplasms: A systematic review and meta-analysis_Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Authors：

HUANG Daxin ^1,2 , HAN Songchen ² , JIN Dacheng ² , WANG Bing ^1,2 , ZHANG Siyuan ^1,2 , YANG Ning ^1,2 , HE Xiaoyang ^1,2 ,  DONG Xinchun ² ,  GOU Yunjiu ²

1. First Department of Clinical Medicine, Gansu University of Chinese Medicine, Lanzhou, 730000, P. R. China;
2. Department of Thoracic Surgery, Gansu Provincial Hospital, Lanzhou, 730000, P. R. China;

Corresponding?author：

DONG Xinchun, Email: 3050319523@qq.com; GOU Yunjiu, Email: gouyunjiu@163.com

Keywords：

Nedaplatin; fluorouracil; cisplatin; esophageal neoplasms; systematic review/meta-analysis

DOI：

10.7507/1007-4848.202012037

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To systematically evaluate the efficacy and safety of nedaplatin versus cisplatin combined with fluorouracil in the treatment of esophageal neoplasms.Methods PubMed, EMbase, Web of Science, The Cochrane Library, CNKI, WanFang, VIP and CBM databases were searched by computer to investigate the randomized controlled studies about the clinical effects of nedaplatin combined with fluorouracil versus cisplatin combined with fluorouracil in the treatment of esophageal neoplasms. The retrieval time was from the establishment of the database to January 2021. And meta-analysis was performed using RevMan 5.4.Results A total of 12 randomized controlled studies involving 744 patients were included. The results of meta-analysis showed that the total effective rate of the nedaplatin group was better than that of the cisplatin group (P<0.05). The incidence of nausea, vomiting, diarrhea and renal impairment in the nedaplatin group was lower than that in the cisplatin group (P<0.05), but the incidence of leukopenia and hemoglobin decline was higher than that in the cisplatin group (P<0.05). There was no statistical difference in the incidence of liver injury, or platelet decline between the two groups (P>0.05).Conclusion Nedaplatin combined with fluorouracil has more advantages than cisplatin combined with fluorouracil in the treatment of esophageal cancer, the incidence of nausea, vomiting and diarrhea is lower, and the damage to kidney function is also smaller.

Citation： HUANG Daxin, HAN Songchen, JIN Dacheng, WANG Bing, ZHANG Siyuan, YANG Ning, HE Xiaoyang, DONG Xinchun, GOU Yunjiu. Efficacy and safety of nedaplatin versus cisplatin plus fluorouracil for treatment of esophageal neoplasms: A systematic review and meta-analysis. Chinese Journal of Clinical Thoracic and Cardiovascular Surgery, 2022, 29(11): 1511-1516. doi: 10.7507/1007-4848.202012037 Copy

1.	Domper Arnal MJ, Ferrández Arenas á, Lanas Arbeloa á. Esophageal cancer: Risk factors, screening and endoscopic treatment in Western and Eastern countries. World J Gastroenterol, 2015, 21(26): 7933-7943.
2.	Alsop BR, Sharma P. Esophageal cancer. Gastroenterol Clin North Am, 2016, 45(3): 399-412.
3.	白雪, 鄭微, 李英濱, 等. 美洛昔康聯合吉非替尼治療食管癌的有效性及安全性分析. 現代腫瘤醫學, 2020, 28(24): 4262-4265.
4.	茍云久, 馬繼龍, 韓松辰, 等. CircHIPK3 通過調控 p53-Akt-Mdm2 通路影響食管鱗癌的惡性表型. 腫瘤防治研究, 2019, 46(11): 987-993.
5.	Zhang F, Wang Y, Wang ZQ, et al. Efficacy and safety of cisplatin-based versus nedaplatin-based regimens for the treatment of metastatic/recurrent and advanced esophageal squamous cell carcinoma: A systematic review and meta-analysis. Dis Esophagus, 2017, 30(2): 1-8.
6.	孫相輝. 奈達鉑聯合5-氟尿嘧啶治療晚期食管癌患者的臨床效果. 中國醫藥指南, 2020, 18(36): 107-108.
7.	Shen ZT, Wu XH, Li B, et al. Nedaplatin concurrent with three-dimensional conformal radiotherapy for treatment of locally advanced esophageal carcinoma. World J Gastroenterol, 2013, 19(48): 9447-9452.
8.	Xu RH, Shi YX, Guan ZZ, et al. Phase Ⅱ clinical trial of home-produced nedaplatin in treating advanced esophageal carcinoma. Ai Zheng, 2006, 25(12): 1565-1568.
9.	房艷. 奈達鉑聯合 5-氟尿嘧啶治療晚期食管癌的療效分析. 中國醫藥指南, 2019, 17(36): 196-197.
10.	劉永玲. 奈達鉑聯合氟尿嘧啶治療晚期食管癌的療效觀察. 中國基層醫藥, 2011, 18(12): 1641-1643.
11.	巴艷華. 奈達鉑聯合 5-氟尿嘧啶治療晚期食管癌38例對免疫功能的影響. 現代診斷與治療, 2019, 30(4): 567-569.
12.	李超. 奈達鉑與 5-氟尿嘧啶聯合用于治療食管癌的療效及安全性分析. 醫學美學美容(中旬刊), 2013, (9): 77-78.
13.	汪俊. 奈達鉑聯合氟尿嘧啶治療晚期食管癌的臨床觀察. 世界最新醫學信息文摘, 2019, 19(25): 112.
14.	薛永飛. 氟尿嘧啶聯合奈達鉑治療晚期食管癌的臨床效果評價. 當代醫學, 2013, (2): 32.
15.	施子夏, 張兵兵, 徐翔宇. 奈達鉑聯合氟尿嘧啶治療晚期食管癌的療效評價. 中國藥業, 2017, 26(7): 52-54.
16.	趙春磊, 王娟. 氟尿嘧啶聯合奈達鉑化療在晚期食管癌治療中的臨床研究. 系統醫學, 2016, 1(3): 8-11.
17.	鄒樂樂, 關紅梅, 楊瑩, 等. 奈達鉑聯合氟尿嘧啶與順鉑聯合氟尿嘧啶治療老年晚期食管癌效果的對比觀察. 中國社區醫師, 2015, 31(34): 21-22.
18.	林明哲, 李欣, 李曉琴, 等. 奈達鉑聯合氟尿嘧啶治療晚期食管癌的療效觀察. 中國衛生產業, 2014, 11(26): 113-114.
19.	劉軻, 崔露瓊, 蔣盼盼, 等. 感染與食管癌的研究進展. 食管疾病, 2020, 2(3): 161-164, 205.
20.	周毅. 奈達鉑聯合氟尿嘧啶方案在晚期食管癌的臨床療效分析. 吉林醫學, 2012, 33(4): 764-765.
21.	Shimada M, Itamochi H, Kigawa J. Nedaplatin: A cisplatin derivative in cancer chemotherapy. Cancer Manag Res, 2013, 5: 67-76.
22.	王珊. 奈達鉑聯合 5-氟尿嘧啶治療食管癌療效與安全性分析. 基層醫學論壇, 2016, 20(4): 490-491.
23.	張質鋼, 王小虎, 楊克虎, 等. 奈達鉑聯合 5-氟尿嘧啶治療晚期食管癌的 Meta 分析. 中國循證醫學雜志, 2013, 13(1): 39-46.
24.	嚴麗華, 吳向坤. 奈達鉑聯合氟尿嘧啶在晚期食管癌治療中的應用價值. 河南醫學研究, 2015, 24(5): 55-56.
25.	馮淑娟. 奈達鉑聯合氟尿嘧啶治療晚期食管癌的臨床療效分析. 中國繼續醫學教育, 2016, 8(3): 162-163.
26.	Zhang Y. Epidemiology of esophageal cancer. World J Gastroenterol, 2013, 19(34): 5598-5606.
27.	孫曉. 奈達鉑聯合氟尿嘧啶在晚期食管癌治療中的臨床應用價值分析. 中國實用醫藥, 2015, 10(5): 162-163.
28.	趙常有. 奈達鉑、氟脲密啶聯合放療治療中晚期食管癌療效觀察. 醫藥前沿, 2016, 6(35): 56-57.

1. Domper Arnal MJ, Ferrández Arenas á, Lanas Arbeloa á. Esophageal cancer: Risk factors, screening and endoscopic treatment in Western and Eastern countries. World J Gastroenterol, 2015, 21(26): 7933-7943.
2. Alsop BR, Sharma P. Esophageal cancer. Gastroenterol Clin North Am, 2016, 45(3): 399-412.
3. 白雪, 鄭微, 李英濱, 等. 美洛昔康聯合吉非替尼治療食管癌的有效性及安全性分析. 現代腫瘤醫學, 2020, 28(24): 4262-4265.
4. 茍云久, 馬繼龍, 韓松辰, 等. CircHIPK3 通過調控 p53-Akt-Mdm2 通路影響食管鱗癌的惡性表型. 腫瘤防治研究, 2019, 46(11): 987-993.
5. Zhang F, Wang Y, Wang ZQ, et al. Efficacy and safety of cisplatin-based versus nedaplatin-based regimens for the treatment of metastatic/recurrent and advanced esophageal squamous cell carcinoma: A systematic review and meta-analysis. Dis Esophagus, 2017, 30(2): 1-8.
6. 孫相輝. 奈達鉑聯合5-氟尿嘧啶治療晚期食管癌患者的臨床效果. 中國醫藥指南, 2020, 18(36): 107-108.
7. Shen ZT, Wu XH, Li B, et al. Nedaplatin concurrent with three-dimensional conformal radiotherapy for treatment of locally advanced esophageal carcinoma. World J Gastroenterol, 2013, 19(48): 9447-9452.
8. Xu RH, Shi YX, Guan ZZ, et al. Phase Ⅱ clinical trial of home-produced nedaplatin in treating advanced esophageal carcinoma. Ai Zheng, 2006, 25(12): 1565-1568.
9. 房艷. 奈達鉑聯合 5-氟尿嘧啶治療晚期食管癌的療效分析. 中國醫藥指南, 2019, 17(36): 196-197.
10. 劉永玲. 奈達鉑聯合氟尿嘧啶治療晚期食管癌的療效觀察. 中國基層醫藥, 2011, 18(12): 1641-1643.
11. 巴艷華. 奈達鉑聯合 5-氟尿嘧啶治療晚期食管癌38例對免疫功能的影響. 現代診斷與治療, 2019, 30(4): 567-569.
12. 李超. 奈達鉑與 5-氟尿嘧啶聯合用于治療食管癌的療效及安全性分析. 醫學美學美容(中旬刊), 2013, (9): 77-78.
13. 汪俊. 奈達鉑聯合氟尿嘧啶治療晚期食管癌的臨床觀察. 世界最新醫學信息文摘, 2019, 19(25): 112.
14. 薛永飛. 氟尿嘧啶聯合奈達鉑治療晚期食管癌的臨床效果評價. 當代醫學, 2013, (2): 32.
15. 施子夏, 張兵兵, 徐翔宇. 奈達鉑聯合氟尿嘧啶治療晚期食管癌的療效評價. 中國藥業, 2017, 26(7): 52-54.
16. 趙春磊, 王娟. 氟尿嘧啶聯合奈達鉑化療在晚期食管癌治療中的臨床研究. 系統醫學, 2016, 1(3): 8-11.
17. 鄒樂樂, 關紅梅, 楊瑩, 等. 奈達鉑聯合氟尿嘧啶與順鉑聯合氟尿嘧啶治療老年晚期食管癌效果的對比觀察. 中國社區醫師, 2015, 31(34): 21-22.
18. 林明哲, 李欣, 李曉琴, 等. 奈達鉑聯合氟尿嘧啶治療晚期食管癌的療效觀察. 中國衛生產業, 2014, 11(26): 113-114.
19. 劉軻, 崔露瓊, 蔣盼盼, 等. 感染與食管癌的研究進展. 食管疾病, 2020, 2(3): 161-164, 205.
20. 周毅. 奈達鉑聯合氟尿嘧啶方案在晚期食管癌的臨床療效分析. 吉林醫學, 2012, 33(4): 764-765.
21. Shimada M, Itamochi H, Kigawa J. Nedaplatin: A cisplatin derivative in cancer chemotherapy. Cancer Manag Res, 2013, 5: 67-76.
22. 王珊. 奈達鉑聯合 5-氟尿嘧啶治療食管癌療效與安全性分析. 基層醫學論壇, 2016, 20(4): 490-491.
23. 張質鋼, 王小虎, 楊克虎, 等. 奈達鉑聯合 5-氟尿嘧啶治療晚期食管癌的 Meta 分析. 中國循證醫學雜志, 2013, 13(1): 39-46.
24. 嚴麗華, 吳向坤. 奈達鉑聯合氟尿嘧啶在晚期食管癌治療中的應用價值. 河南醫學研究, 2015, 24(5): 55-56.
25. 馮淑娟. 奈達鉑聯合氟尿嘧啶治療晚期食管癌的臨床療效分析. 中國繼續醫學教育, 2016, 8(3): 162-163.
26. Zhang Y. Epidemiology of esophageal cancer. World J Gastroenterol, 2013, 19(34): 5598-5606.
27. 孫曉. 奈達鉑聯合氟尿嘧啶在晚期食管癌治療中的臨床應用價值分析. 中國實用醫藥, 2015, 10(5): 162-163.
28. 趙常有. 奈達鉑、氟脲密啶聯合放療治療中晚期食管癌療效觀察. 醫藥前沿, 2016, 6(35): 56-57.

Previous Article
The effect of blood type of colorectal patients on long-term survival: a real-world study based on DACCA database
Next Article
胰腺頸部Castleman病1例報道

Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Efficacy and safety of nedaplatin versus cisplatin plus fluorouracil for treatment of esophageal neoplasms: A systematic review and meta-analysis

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content